{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:30:44Z","timestamp":1760189444924},"reference-count":30,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2015,11,16]],"date-time":"2015-11-16T00:00:00Z","timestamp":1447632000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Acta Neuropsychiatr."],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:sec id=\"S0924270815000605_abs1\" sec-type=\"general\"><jats:title>Objective<\/jats:title><jats:p>The present paper is devoted to evaluation of clinical and immunomodulatory effect of ultra-high dilutions of antibodies to human interferon \u03b3, included in the complex therapy of patients with schizophrenia.<\/jats:p><\/jats:sec><jats:sec id=\"S0924270815000605_abs2\" sec-type=\"materialsandmethods\"><jats:title>Materials and methods<\/jats:title><jats:p>The study was carried out at the Mental Health Research Institute, Tomsk, Russian Federation. This double-blind, placebo-controlled randomised in parallel-group study enrolled 40 patients. As a part of complex therapy, patients from the main group (<jats:italic>n<\/jats:italic>=20) received anaferon, a drug containing ultra-high dilutions of affinity-purified antibodies to human interferon \u03b3 as the active pharmaceutical ingredient; patients from the comparative group (<jats:italic>n<\/jats:italic>=20) received placebo. Duration of the therapy was 30\u00b15 days. Assessment of severity of symptoms and changes in them were made using clinical scales: Positive and Negative Syndrome Scale, Clinical Global Impression, Abnormal Involuntary Movements Scale. Spontaneous and phytohemagglutinin-induced production of interferon \u03b3 by immunocompetent cells in supernatants of 48 h whole blood culture of patients was measured by enzyme-linked immunosorbent assay (ELISA) method.<\/jats:p><\/jats:sec><jats:sec id=\"S0924270815000605_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>The reduction of interferon-producing potential by immunocompetent cells in comparison with reference normal value was shown in total group of patients (<jats:italic>n<\/jats:italic>=40) before combined therapy. During the treatment, increase of spontaneous interferon \u03b3 production and favourable changes in psychopathological symptoms as compared with placebo were shown in subjects receiving anaferon. It was found that favourable changes in clinical symptoms assessed using clinical scales with a high degree of confidence correlated with high level of spontaneous interferon \u03b3 production.<\/jats:p><\/jats:sec><jats:sec id=\"S0924270815000605_abs4\" sec-type=\"conclusion\"><jats:title>Conclusion<\/jats:title><jats:p>Anaferon as a part of complex therapy of patients with schizophrenia contributes to enhancement of its efficacy acting via mechanism of psychoimmunomodulation.<\/jats:p><\/jats:sec>","DOI":"10.1017\/neu.2015.60","type":"journal-article","created":{"date-parts":[[2015,11,16]],"date-time":"2015-11-16T09:38:26Z","timestamp":1447666706000},"page":"149-156","update-policy":"http:\/\/dx.doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":8,"title":["Adjunctive use of interferon \u03b3 inducer for treatment of patients with schizophrenia"],"prefix":"10.1017","volume":"28","author":[{"given":"Tamara Parfenovna","family":"Vetlugina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga Anatolyevna","family":"Lobacheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana Alexandrovna","family":"Sergeeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina Borisovna","family":"Nikitina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana Ivanovna","family":"Nevidimova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkady Valentinovich","family":"Semke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2015,11,16]]},"reference":[{"key":"S0924270815000605_ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2010.02094.x"},{"key":"S0924270815000605_ref11","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105048905"},{"key":"S0924270815000605_ref26","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-030409-101212"},{"key":"S0924270815000605_ref29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.schres.2014.12.037","article-title":"Altered IL-2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia","volume":"162","author":"HM","year":"2015","journal-title":"Schizophr Res"},{"key":"S0924270815000605_ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000111535"},{"key":"S0924270815000605_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2014.01.017"},{"key":"S0924270815000605_ref6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.15690\/vramn.v67i12.475","article-title":"Clinical and experimental research of immunomodulatory effect of amisulpride","volume":"12","author":"Vetlugina","year":"2012","journal-title":"Vestn Ross Akad Med Nauk"},{"key":"S0924270815000605_ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10517-009-0704-y"},{"key":"S0924270815000605_ref1","doi-asserted-by":"publisher","DOI":"10.1177\/026988119300700412"},{"key":"S0924270815000605_ref10","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200301000-00002"},{"key":"#cr-split#-S0924270815000605_ref20.1","unstructured":"1. Vetlugina TP, Lobacheva OA, Semke AV, Sergeeva SA, Ehpshtejn OI, Mal'tseva JL . Method of treating patients with schizophrenia. Ru Patent 2415666 C1 2011. Oficial'nyj bjulleten' \"Federal'nogo instituta promyshlennoj sobstvennosti\" \"Izobretenija. Poleznye modeli\" [Official Bulletin of the Federal Institute of Industrial Property \"Inventions. Useful Models\"]. 2011"},{"key":"#cr-split#-S0924270815000605_ref20.2","unstructured":"2. No. 10. http:\/\/www1.fips.ru\/Archive\/PAT\/2011FULL\/2011.04.10\/DOC\/RUNWC1\/000\/000\/002\/415\/666\/document.pdf (In Russian)."},{"key":"S0924270815000605_ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2000.tb05410.x"},{"key":"S0924270815000605_ref2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.317"},{"key":"S0924270815000605_ref15","volume-title":"Pharmacology of ultralow doses of antibodies to endogenous function regulators","author":"Epstein","year":"2005"},{"key":"S0924270815000605_ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-010-0098-x"},{"key":"S0924270815000605_ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.11.018"},{"key":"S0924270815000605_ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10517-009-0699-4"},{"key":"S0924270815000605_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2011.12.049"},{"key":"S0924270815000605_ref13","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6882-12-191"},{"key":"S0924270815000605_ref25","first-page":"54","article-title":"The phenomenon of release activity and the hypothesis of \u2018spatial\u2019 homeostasis","volume":"44","author":"Epstein","year":"2013","journal-title":"Usp Fiziol Nauk"},{"key":"S0924270815000605_ref14","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024709014483"},{"key":"S0924270815000605_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2006.07.006"},{"key":"S0924270815000605_ref27","doi-asserted-by":"publisher","DOI":"10.1177\/070674370505000907"},{"key":"S0924270815000605_ref22","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.pnpbp.2004.05.047","article-title":"Th1, Th2 and Th3 cytokine alteration in schizophrenia","volume":"28","author":"YK","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"S0924270815000605_ref5","first-page":"253","article-title":"Immunology in schizophrenic disorders","volume":"78","author":"M\u0171ller","year":"2007","journal-title":"Nervenarzt"},{"key":"S0924270815000605_ref21","volume-title":"Standards for medical assistance to subjects with schizophrenia","author":"Krasnov","year":"2006"},{"key":"S0924270815000605_ref24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-12-13"},{"key":"S0924270815000605_ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-008-9114-5"},{"key":"S0924270815000605_ref16","volume-title":"Ultralow doses (the story of one study)","author":"Epstein","year":"2008"}],"container-title":["Acta Neuropsychiatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924270815000605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T11:51:01Z","timestamp":1599825061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924270815000605\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,16]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0924270815000605"],"URL":"https:\/\/doi.org\/10.1017\/neu.2015.60","relation":{},"ISSN":["0924-2708","1601-5215"],"issn-type":[{"value":"0924-2708","type":"print"},{"value":"1601-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,16]]},"assertion":[{"value":"\u00a9 Scandinavian College of Neuropsychopharmacology 2015\u00a0","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}